Which medication is a biguanide commonly used to treat type 2 diabetes mellitus?

Prepare for the Certification in Clinical Sleep Health exam. Use flashcards and multiple-choice questions with hints and explanations. Ace your exam!

Multiple Choice

Which medication is a biguanide commonly used to treat type 2 diabetes mellitus?

Understanding which medication is a biguanide used for type 2 diabetes centers on recognizing the drug class and its typical role in treatment. Metformin is the biguanide commonly prescribed as first-line therapy because it lowers hepatic glucose production (gluconeogenesis) and improves insulin sensitivity in muscle and fat, helping glucose enter cells. Because its effect isn’t reliant on increasing insulin secretion, it usually does not cause hypoglycemia when used alone. The other drugs listed belong to different classes: Actos is a thiazolidinedione that also improves insulin sensitivity but through a different mechanism; Januvia is a DPP-4 inhibitor that increases incretin hormones to boost insulin release; Byetta is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion and slows gastric emptying. Metformin is typically favored for weight considerations and broad tolerability, though it can cause GI upset and carries a rare risk of lactic acidosis, especially with kidney impairment, so renal function should be monitored and it may be paused around certain imaging procedures.

Understanding which medication is a biguanide used for type 2 diabetes centers on recognizing the drug class and its typical role in treatment. Metformin is the biguanide commonly prescribed as first-line therapy because it lowers hepatic glucose production (gluconeogenesis) and improves insulin sensitivity in muscle and fat, helping glucose enter cells. Because its effect isn’t reliant on increasing insulin secretion, it usually does not cause hypoglycemia when used alone. The other drugs listed belong to different classes: Actos is a thiazolidinedione that also improves insulin sensitivity but through a different mechanism; Januvia is a DPP-4 inhibitor that increases incretin hormones to boost insulin release; Byetta is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion and slows gastric emptying. Metformin is typically favored for weight considerations and broad tolerability, though it can cause GI upset and carries a rare risk of lactic acidosis, especially with kidney impairment, so renal function should be monitored and it may be paused around certain imaging procedures.

More practice questions